Ankersen et al., PMID 9733495) anchor the adverse-event picture
According to FDA-approved prescribing information, gastrointestinal adverse effects occur commonly with these medications, with nausea reported in 16-44% of patients, vomiting in 6-24%, and abdominal pain or distension in 5-18%, depending on the specific medication and dosage
Warning Signs to Watch For If you do choose to drink while on GLP-1 therapy, Agrawal advises stopping and seeking medical advice if you experience: Dizziness, confusion, sweating, shakiness, or slurred speech Severe or persistent nausea and vomiting Abdominal pain that could suggest pancreatitis Feeling unusually impaired despite drinking a small amount Worsened hangovers compared to your normal experience Trouble thinking clearly or coordinating movements Any of these symptoms are a reason to stop drinking and seek medical guidance, Agrawal says
Patients should not expect tirzepatide to function as a treatment for conditions of cortisol excess such as Cushing's syndrome, which requires specific diagnostic evaluation and targeted therapeutic interventions
Semaglutide and other weight loss medications mimic the action of this hormone
DePietro and Salzberg, 2022